Sanofi Signals Willingness for Larger Deals as New CEO Prepares for Post-Dupixent Era
Under new CEO Garijo, Sanofi says it may pursue larger acquisitions while lifting 2026 growth targets after strong Dupixent-led Q3 results.
Under new CEO Garijo, Sanofi says it may pursue larger acquisitions while lifting 2026 growth targets after strong Dupixent-led Q3 results.
Revenue grew 36% and non-GAAP EPS rose 70% on record Dupixent and EYLEA HD sales.
Amgen and AstraZeneca’s Tezspire showed high histologic remission and symptom improvement in Phase 3 EoE trial, positioning it as a potential Dupixent rival.
Eli Lilly, Merck, AbbVie, and UnitedHealth rose as markets fell on stronger inflation data, highlighting healthcare’s defensive strength.
Positive 84-week OPTIMA data for Pasatru lifted Regeneron shares, confirming sustained reduction in new heterotopic ossification and flare-ups.
Zenkuda was non-inferior to Eylea in vision, dried fluid quickly, and put 54% of wet AMD patients on 24-week dosing under strict treat-to-dryness rules.